The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events

The Load of Amyloid-β Oligomers is Decreased in the Cerebrospinal Fluid of Alzheimer's Disease Patients

(2018) Giulia M. Sancesario et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid-β Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease

(2018) Alexander Navarrete Santos et al.   JOURNAL OF ALZHEIMERS DISEASE

A Candidate Plasma Protein Classifier to Identify Alzheimer's Disease

(2018) Xuemei Zhao et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays

(2018) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

(2015) Hlin Kvartsberg et al.   Alzheimers & Dementia

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding

(2015) Kaj Blennow et al.   NATURE MEDICINE

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

(2015) Julien Dumurgier et al.   Alzheimers Research & Therapy

A Sensitive A  Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid

(2014) M. J. Savage et al.   JOURNAL OF NEUROSCIENCE

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

(2014) Ann Brinkmalm et al.   Molecular Neurodegeneration

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease

(2014) Ronald Lautner et al.   JAMA Psychiatry

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

(2014) Niklas Mattsson et al.   Annals of Clinical and Translational Neurology

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

The future of blood-based biomarkers for Alzheimer's disease

(2013) Kim Henriksen et al.   Alzheimers & Dementia

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

(2013) Alan Rembach et al.   Alzheimers & Dementia

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

(2013) Mikko Hölttä et al.   PLoS One

ApoE influences amyloid-  (A ) clearance despite minimal apoE/A  association in physiological conditions

(2013) P. B. Verghese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Correlation of Specific Amyloid-β Oligomers With Tau in Cerebrospinal Fluid From Cognitively Normal Older Adults

(2013) Maureen Handoko et al.   JAMA Neurology

Comparison of International Working Group criteria and National Institute on Aging–Alzheimer’s Association criteria for Alzheimer’s disease

(2012) Pieter Jelle Visser et al.   Alzheimers & Dementia

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

(2012) Maria C. Carrillo et al.   Alzheimers & Dementia

Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue

(2012) Kim A. Bruggink et al.   ANALYTICAL BIOCHEMISTRY

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Clinical Chemistry and Laboratory Medicine: an appreciation

(2012) Graham H. Beastall et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Molecular machines governing exocytosis of synaptic vesicles

(2012) Reinhard Jahn et al.   NATURE

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

(2012) I. A. van Rossum et al.   NEUROLOGY

Age and diagnostic performance of Alzheimer disease CSF biomarkers

(2012) N. Mattsson et al.   NEUROLOGY

Synaptic changes in Alzheimer’s disease and its models

(2012) J. Pozueta et al.   NEUROSCIENCE

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

(2011) William E. Klunk   NEUROBIOLOGY OF AGING

Soluble amyloid  -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

(2011) M. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human apoE Isoforms Differentially Regulate Brain Amyloid-  Peptide Clearance

(2011) J. M. Castellano et al.   Science Translational Medicine

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

(2010) Annika Thorsell et al.   BRAIN RESEARCH

High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

(2010) Hiroaki Fukumoto et al.   FASEB JOURNAL

Biomarkers in Alzheimer's disease drug development

(2010) Kaj Blennow   NATURE MEDICINE

Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease

(2010) Carol Man Gao et al.   PLoS One

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type

(2009) Barbara J. Snider et al.   ARCHIVES OF NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

Amyloid   Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

(2008) I. Klyubin et al.   JOURNAL OF NEUROSCIENCE

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses

(2008) Lars Bertram et al.   NATURE REVIEWS NEUROSCIENCE

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

(2007) Miroslaw Brys et al.   NEUROBIOLOGY OF AGING